Low dose aspirin and cognitive function in the women's health study cognitive cohort - PubMed (original) (raw)

Randomized Controlled Trial

. 2007 May 12;334(7601):987.

doi: 10.1136/bmj.39166.597836.BE. Epub 2007 Apr 27.

Affiliations

Randomized Controlled Trial

Low dose aspirin and cognitive function in the women's health study cognitive cohort

Jae Hee Kang et al. BMJ. 2007.

Abstract

Objective: To determine whether low dose aspirin protects women aged 65 or more against cognitive decline.

Design: Cohort study within both arms of the women's health study, a randomised, double blind, placebo controlled trial of low dose aspirin for the primary prevention of cardiovascular disease and cancer, 1992-5.

Setting: Women's health study, 1998-2004.

Participants: 6377 women aged 65 or more.

Interventions: Low dose aspirin (100 mg on alternate days) or placebo for a mean of 9.6 years.

Main outcome measures: Women had three cognitive assessments at two year intervals by telephone. The battery to assess cognition included five tests measuring general cognition, verbal memory, and category fluency. The primary prespecified outcome was a global score, averaging performance across all tests. The key secondary outcome was a verbal memory score, averaging performance on four measures of verbal memory.

Results: At the initial assessment (mean 5.6 years after randomisation) cognitive performance in the aspirin group was similar to that of the placebo group (mean difference in global score -0.01, 95% confidence interval -0.04 to 0.02). Mean decline in the global score from the first to the final cognitive assessment was also similar in the aspirin compared with placebo groups (mean difference 0.01, -0.02 to 0.04). The risk of substantial decline (in the worst 10th centile of decline) was also comparable between the groups (relative risk 0.92, 0.77 to 1.10). Findings were similar for verbal memory; however, a 20% lower risk was observed for decline in category fluency with aspirin (relative risk 0.80, 0.67 to 0.97).

Conclusion: Long term use of low dose aspirin does not provide overall benefits for cognition among generally healthy women aged 65 or more.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

None

Flow chart of participation in cognitive cohort of women's health study

Comment in

Similar articles

Cited by

References

    1. Small BJ, Fratiglioni L, Viitanen M, Winblad B, Backman L. The course of cognitive impairment in preclinical Alzheimer disease: three- and 6-year follow-up of a population based sample. Arch Neurol 2000;57:839-44. - PubMed
    1. Amieva H, Jacqmin-Gadda H, Orgogozo J-M, Le Carret N, Helmer C, Letenneur L, et al. The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study. Brain 2005;128:1093-101. - PubMed
    1. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43:1609-11. - PubMed
    1. Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 1999;53:197-201. - PubMed
    1. Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, et al. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's disease cooperative study. Neurology 2000;54:588-93. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources